Huron to acquire Eclipse Insights, bolstering healthcare revenue cycle

Published 18/06/2025, 14:30
Huron to acquire Eclipse Insights, bolstering healthcare revenue cycle

CHICAGO - Professional services firm Huron (NASDAQ:HURN), a $2.18 billion market cap company with approximately 9% revenue growth over the last twelve months, announced Wednesday it has entered into an agreement to acquire Eclipse Insights, a revenue cycle consulting firm specializing in helping healthcare organizations maximize revenue and improve cash flow.

The acquisition will enhance Huron’s capabilities in delivering end-to-end revenue cycle solutions for healthcare providers facing margin pressures, workforce shortages, declining reimbursements, and rising insurance claim denials. According to InvestingPro analysis, Huron maintains excellent financial health with a "GREAT" overall score, supported by a strong current ratio of 2.08.

Eclipse Insights brings expertise in charge capture, clinical documentation, coding, and denials management, complementing Huron’s existing capabilities across the revenue cycle continuum from patient access to reimbursement.

"Eclipse Insights’ deep mid-revenue cycle expertise strengthens our ability to deliver a comprehensive, end-to-end revenue cycle solution that improves financial performance," said Mark Hussey, chief executive officer and president of Huron.

Approximately 40 members of the Eclipse Insights team will join Huron as part of the deal. The acquisition will be included in Huron’s Healthcare operating segment and is expected to close later this month.

Shannon Yasseri, founder of Eclipse Insights, stated, "Joining Huron enables us to broaden our reach and deepen our impact with clients who need trusted experts now more than ever."

Financial terms of the acquisition were not disclosed, according to the press release statement. InvestingPro data shows Huron trading at a P/E ratio of 21.4, with analysts maintaining positive forecasts for the company’s profitability this year. For deeper insights into Huron’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

In other recent news, Huron Consulting Group reported strong first-quarter 2025 financial results, exceeding analysts’ expectations. The company achieved an earnings per share (EPS) of $1.68, surpassing the anticipated $1.16, and recorded revenue of $395.7 million, above the expected $389.27 million. Following these results, Huron reaffirmed its full-year guidance for 2025, projecting revenue between $1.58 billion and $1.66 billion. Additionally, Huron’s stockholders approved an amendment to the company’s Omnibus Incentive Plan, increasing the authorized shares by 900,000. This decision was part of several key matters voted on during the recent Annual Meeting. Meanwhile, Benchmark analysts maintained their Buy rating for Huron, citing a stable outlook after discussions at a recent healthcare conference. The analysts highlighted that recent government actions have had a neutral-to-positive impact on Huron’s business, particularly within its Healthcare and Education segments. Huron also reported acceleration in sales conversions in its Healthcare segment, focusing on Revenue Cycle Management and efficiency projects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.